keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/28221194/multiple-time-point-68-ga-psma-i-t-pet-ct-for-characterization-of-primary-prostate-cancer-value-of-early-dynamic-and-delayed-imaging
#1
Sebastian Schmuck, Martin Mamach, Florian Wilke, Christoph A von Klot, Christoph Henkenberens, James T Thackeray, Jan M Sohns, Lilli Geworski, Tobias L Ross, Hans-Juergen Wester, Hans Christiansen, Frank M Bengel, Thorsten Derlin
PURPOSE: The aims of this study were to gain mechanistic insights into prostate cancer biology using dynamic imaging and to evaluate the usefulness of multiple time-point Ga-prostate-specific membrane antigen (PSMA) I&T PET/CT for the assessment of primary prostate cancer before prostatectomy. METHODS: Twenty patients with prostate cancer underwent Ga-PSMA I&T PET/CT before prostatectomy. The PET protocol consisted of early dynamic pelvic imaging, followed by static scans at 60 and 180 minutes postinjection (p...
February 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28217987/radiolabelled-psma-small-molecule-inhibitors
#2
Leon Will, Ida Sonni, Klaus Kopka, Clemens Kratochwil, Frederik L Giesel, Uwe Haberkorn
INTRODUCTION: Prostate cancer (PC) is one of the most common malignancies worldwide. Prostate-specific membrane antigen (PSMA) has been found to be expressed in most PCs and represents an ideal target for radiolabeling with diagnostic and therapeutic purposes. Numerous PSMA-tracers have been recently developed. This systematic review aims to provide an overview on the clinical influence of PSMA-tracers in primary staging, biochemical recurrence (BCR) of PC and advanced, metastatic PC...
February 17, 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28217012/-68-ga-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-for-prostate-cancer-imaging-a-narrative-literature-review
#3
REVIEW
Jose M Oliveira, Catarina Gomes, Diogo B Faria, Tiago S Vieira, Fernando A Silva, Joana Vale, Francisco L Pimentel
The (68)Ga-prostate-specific membrane antigen ( (68)Ga-PSMA) has been recently developed to be used, as a ligand, in positron emission tomography/computed tomography (PET/CT) prostate cancer imaging, to detect prostate disease. The main objective of this review was to collect data and findings from other studies and articles to assess, theoretically, if (68)GA-PSMA PET/CT is a more appropriate prostate cancer diagnostic technique in comparison with others available such as CT, (18)F-fluoro-2-deoxyglucose PET/CT, or (18)F-fluoromethylcholine ( (18)F-choline) PET/CT...
January 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28209912/detection-efficacy-of-hybrid-68-ga-psma-ligand-pet-ct-in-prostate-cancer-patients-with-biochemical-recurrence-after-primary-radiation-therapy-defined-by-phoenix-criteria
#4
Ingo Einspieler, Isabel Rauscher, Charlotte Düwel, Markus Krönke, Christoph Rischpler, Gregor Habl, Sabrina Dewes, Armin Ott, Hans-Jürgen Wester, Markus Schwaiger, Tobias Maurer, Matthias Eiber
The aim of this retrospective study was to evaluate the detection rate of Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA ligand) positron emission tomography/computed tomography (PET/CT) in patients with biochemical recurrent prostate cancer (PC) defined by Phoenix criteria after external beam radiotherapy (EBRT) or brachytherapy as primary treatment. Methods: 118 patients were finally eligible for this retrospective analysis with a median prostate-specific antigen (PSA) of 6.4 ng/mL (range: 2.2-158...
February 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28197764/new-frontiers-in-prostate-cancer-imaging-clinical-utility-of-prostate-specific-membrane-antigen-positron-emission-tomography
#5
REVIEW
Asim Afaq, Deepak Batura, Jamshed Bomanji
Prostate-specific membrane antigen positron emission tomography (PSMA PET) is a relatively new method of imaging prostate cancer that increases diagnostic accuracy in detecting and guiding management in various stages of the disease pathway. Gallium-68-labelled PSMA PET has increased the sensitivity of detection of disease recurrence at low PSA levels, thus allowing an optimal window for salvage treatment. Apart from its use in disease recurrence, PSMA PET has the potential for increasing sensitivity and specificity for primary tumour localisation and in detecting lymph node disease, leading to a more accurate initial staging of the condition...
February 14, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28195907/solitary-psma-positive-pulmonary-metastasis-in-biochemical-relapse-of-prostate-cancer
#6
Nils Groe Hokamp, Carsten Kobe, Eric Linzenich, David Maintz, Alexander Drzezga
A 63-year-old man with a history of prostate cancer, treated with resection, radiation, and androgen-depriving therapy over 4 years, was referred to our department with suspicion of recurrence based on increased blood PSA levels (1.60 ng/mL). Ga PSMA PET/CT identified a solitary, PSMA-positive pulmonary nodule in the right lung. After resection, histologic analysis confirmed prostatic origin, and the blood PSA level decreased to 0.13 ng/mL. Solitary pulmonary metastasis from prostate cancer is rare. The benefits of local treatment of a single metastasis even in advanced disease are disputed among oncologists...
February 13, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28193503/clinical-translation-of-a-psma-inhibitor-for-99m-tc-based-spect
#7
Guillermina Ferro-Flores, Myrna Luna-Gutiérrez, Blanca Ocampo-García, Clara Santos-Cuevas, Erika Azorín-Vega, Nallely Jiménez-Mancilla, Emmanuel Orocio-Rodríguez, Jenny Davanzo, Francisco O García-Pérez
BACKGROUND: Prostate-specific membrane antigen (PSMA) is highly over-expressed in advanced prostate cancers. (68)Ga-labeled PSMA inhibitors (iPSMA) are currently used for prostate cancer detection by PET imaging. The availability of simple, efficient and reproducible radiolabeling procedures is essential for developing new SPECT radiopharmaceuticals for clinical translation. The aim of this research was to prepare (99m)Tc-EDDA/HYNIC-Lys(Nal)-Urea-Glu ((99m)Tc-EDDA/HYNIC-iPSMA) obtained from lyophilized kit formulations and evaluate the in vitro and in vivo radiopharmaceutical binding to prostate cancer cells over-expressing PSMA, as well as the (99m)Tc-EDDA/HYNIC-iPSMA normal biodistribution in humans and the preliminary uptake in patients with prostate cancer...
February 3, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28193277/anti-tumor-effects-of-a-recombinant-anti-prostate-specific-membrane-antigen-immunotoxin-against-prostate-cancer-cells
#8
Ping Meng, Qing-Chuan Dong, Guang-Guo Tan, Wei-Hong Wen, He Wang, Geng Zhang, Yan-Zhu Wang, Yu-Ming Jing, Chen Wang, Wei-Jun Qin, Jian-Lin Yuan
BACKGROUND: To evaluate anti-prostate cancer effects of a chimeric tumor-targeted killer protein. METHODS: We established a novel fusion gene, immunocasp-3, composed of NH2-terminal leader sequence fused with an anti-prostate-specific membrane antigen (PSMA) antibody (J591), the furin cleavage sequences of diphtheria toxin (Fdt), and the reverse coding sequences of the large and small subunits of caspase-3 (revcaspase-3). The expressing level of the immunocasp-3 gene was evaluated by using the reverse transcription-PCR (RT-PCR) and western blot analysis...
February 13, 2017: BMC Urology
https://www.readbyqxmd.com/read/28191563/dendritic-poly-chelator-frameworks-for-multimeric-bioconjugation
#9
Dominik Reich, Alexander Wurzer, Martina Wirtz, Veronika Stiegler, Philipp Spatz, Julia Pollmann, Hans-Jürgen Wester, Johannes Notni
Starting from multifunctional triazacyclononane-triphosphinate chelator cores, dendritic molecules with the ability to bind metal ions within their framework were synthesized. A cooperative interaction of the chelator cages resulted in a markedly increased affinity towards (67/68)Ga(III). A hexameric PSMA inhibitor conjugate with high affinity (IC50 = 1.2 nM) and favorable in vivo PET imaging properties demonstrated practical applicability. The novel scaffolds are useful for synthesis of structurally well-defined multimodal imaging probes or theranostics...
February 13, 2017: Chemical Communications: Chem Comm
https://www.readbyqxmd.com/read/28168589/impact-of-pet-acquisition-durations-on-image-quality-and-lesion-detectability-in-whole-body-68-ga-psma-pet-mri
#10
Benjamin Noto, Florian Büther, Katharina Auf der Springe, Nemanja Avramovic, Walter Heindel, Michael Schäfers, Thomas Allkemper, Lars Stegger
BACKGROUND: While (68)Ga-PSMA PET-MRI might be superior to PET-CT with regard to soft tissue assessment in prostate cancer evaluation, it is also known to potentially introduce additional PET image artefacts. Therefore, the impact of PET acquisition duration and attenuation data on artefact occurrence, lesion detectability, and quantification was investigated. To this end, whole-body PET list mode data from 12 patients with prostate cancer were acquired 1 h after injection of 2 MBq/kg [(68)Ga]HBED-CC-PSMA on a hybrid PET-MRI system...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28166149/incidental-detection-of-head-and-neck-squamous-cell-carcinoma-on-68ga-psma-11-pet-ct
#11
Courtney Lawhn-Heath, Robert R Flavell, Christine Glastonbury, Thomas A Hope, Spencer C Behr
We present a case of an incidentally detected squamous cell carcinoma of the oropharynx on Ga-PSMA-11 PET. A 71-year-old man's condition was diagnosed as prostate carcinoma after a year of rising serum prostate-specific antigen. The staging Ga-PSMA PET/CT demonstrated focal radiotracer uptake in the prostate corresponding to his known primary prostate cancer. However, a PSMA-avid 3.4-cm mass was incidentally found in the right tongue base that was biopsied, confirming squamous cell carcinoma.
February 3, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28145499/targeted-nanoparticles-encapsulating-epigallocatechin-3-gallate-for-prostate-cancer-prevention-and-therapy
#12
Vanna Sanna, Chandra K Singh, Rahime Jashari, Vaqar M Adhami, Jean Christopher Chamcheu, Islam Rady, Mario Sechi, Hasan Mukhtar, Imtiaz A Siddiqui
Earlier we introduced the concept of 'nanochemoprevention' i.e. the use of nanotechnology to improve the outcome of cancer chemoprevention. Here, we extended our work and developed polymeric EGCG-encapsulated nanoparticles (NPs) targeted with small molecular entities, able to bind to prostate specific membrane antigen (PSMA), a transmembrane protein that is overexpressed in prostate cancer (PCa), and evaluated their efficacy in preclinical studies. First, we performed a molecular recognition of DCL- and AG-PEGylation on ligand binding on PSMA active site...
February 1, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28138747/-68-ga-psma-11-pet-ct-in-primary-staging-of-prostate-cancer-psa-and-gleason-score-predict-the-intensity-of-tracer-accumulation-in-the-primary-tumour
#13
Christian Uprimny, Alexander Stephan Kroiss, Clemens Decristoforo, Josef Fritz, Elisabeth von Guggenberg, Dorota Kendler, Lorenza Scarpa, Gianpaolo di Santo, Llanos Geraldo Roig, Johanna Maffey-Steffan, Wolfgang Horninger, Irene Johanna Virgolini
PURPOSE: Prostate cancer (PC) cells typically show increased expression of prostate-specific membrane antigen (PSMA), which can be visualized by (68)Ga-PSMA-11 PET/CT. The aim of this study was to assess the intensity of (68)Ga-PSMA-11 uptake in the primary tumour and metastases in patients with biopsy-proven PC prior to therapy, and to determine whether a correlation exists between the primary tumour-related (68)Ga-PSMA-11 accumulation and the Gleason score (GS) or prostate-specific antigen (PSA) level...
January 31, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28134694/pulmonary-opacities-and-bronchiectasis-avid-on-68ga-psma-pet
#14
Kirsten Bouchelouche, Mikkel Holm Vendelbo
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and the expression increases with tumor aggressiveness, metastatic disease, and recurrence. Despite its name, PSMA is also expressed in neovasculature of other tumors including lung cancer. Here, we demonstrate a case of increased PSMA expression on Ga-PSMA PET/CT in benign lung opacities and bronchiectasis in a prostate cancer patient. Thus, increased PSMA activity in the lungs may be due to both benign and malignant diseases and warrants further evaluation...
January 27, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28131751/18f-psma-1007-pet-ct-detects-micrometastases-in-a-patient-with-biochemically-recurrent-prostate-cancer
#15
Frederik L Giesel, Claudia Kesch, Mijin Yun, Jens Cardinale, Uwe Haberkorn, Klaus Kopka, Clemens Kratochwil, Boris A Hadaschik
No abstract text is available yet for this article.
December 29, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28131698/incidental-detection-of-tracer-avidity-in-meningioma-in-68-ga-psma-pet-ct-during-initial-staging-for-prostate-cancer
#16
T K Jain, A G S Jois, S Kumar V, S K Singh, R Kumar, B R Mittal
No abstract text is available yet for this article.
January 25, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28128882/co-delivery-of-docetaxel-and-p44-42-mapk-sirna-using-psma-antibody-conjugated-bsa-pei-layer-by-layer-nanoparticles-for-prostate-cancer-target-therapy
#17
See-Tong Pang, Feng-Wei Lin, Cheng-Keng Chuang, Hung-Wei Yang
How to overcome the low accumulation of chemotherapeutic agent in tumor tissue and exhibit multitherapeutics remains an ongoing challenge for cancer treatment. Here, a simple method is demonstrated that used to prepare prostate-specific membrane antigen antibody (PSMAab )-conjugated fluorescent bovine serum albumin (BSA)-branched polyethylenimine layer-by-layer nanoparticles (BSA-PEILBL NPs) for co-delivery of docetaxel (DTX) and p44/42 mitogen-activated protein kinase (MAPK) small interfering RNA (p44/42 MAPK siRNA) as synergistic and selective inhibition of cancer cell proliferation platform...
January 27, 2017: Macromolecular Bioscience
https://www.readbyqxmd.com/read/28126683/pet-imaging-of-64-cu-dota-scfv-anti-psma-lipid-nanoparticles-lnps-enhanced-tumor-targeting-over-anti-psma-scfv-or-untargeted-lnps
#18
Patty Wong, Lin Li, Junie Chea, Melissa K Delgado, Desiree Crow, Erasmus Poku, Barbara Szpikowska, Nicole Bowles, Divya Channappa, David Colcher, Jeffrey Y C Wong, John E Shively, Paul J Yazaki
INTRODUCTION: Single chain (scFv) antibodies are ideal targeting ligands due to their modular structure, high antigen specificity and affinity. These monovalent ligands display rapid tumor targeting but have limitations due to their fast urinary clearance. METHODS: An anti-prostate membrane antigen (PSMA) scFv with a site-specific cysteine was expressed and evaluated in a prostate cancer xenograft model by Cu-64 PET imaging. To enhance tumor accumulation, the scFv-cys was conjugated to the co-polymer DSPE-PEG-maleimide that spontaneously assembled into a homogeneous multivalent lipid nanoparticle (LNP)...
January 17, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28116853/utility-of-68-ga-prostate-specific-membrane-antigen-positron-emission-tomography-in-diagnosis-and-response-assessment-of-recurrent-renal-cell-carcinoma
#19
Shankar Siva, Jason Callahan, David Pryor, Jarad Martin, Nathan Lawrentschuk, Michael S Hofman
INTRODUCTION: Prostate specific membrane antigen (PSMA) positron emission tomography (PET) is an emerging imaging modality in prostate cancer. However, (68) Ga-PSMA-PET may also have diagnostic utility in the setting of renal cell carcinoma (RCC). We investigate the differential role of (18) F-fluorodeoxyglucose (FDG) and PSMA-PET/CT scanning in patients with oligometastatic RCC. In particular, we focus on the utility of PSMA-PET for diagnostic evaluation of isolated or limited metastases planned for local surgery or radiation, as well as the potential utility of PSMA-PET for therapeutic response assessment in patients receiving stereotactic ablative body radiotherapy (SABR)...
January 24, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28116598/enterolactone-glucuronide-and-%C3%AE-glucuronidase-in-antibody-directed-enzyme-prodrug-therapy-for-targeted-prostate-cancer-cell-treatment
#20
Yunyun Di, Shaoping Ji, Philipp Wolf, Ed S Krol, Jane Alcorn
Evidence from preclinical and animal studies demonstrated an anticancer effect of flaxseed lignans, particularly enterolactone (ENL), against prostate cancer. However, extensive first-pass metabolism following oral lignan consumption results in their systemic availability primarily as glucuronic acid conjugates (ENL-Gluc) and their modest in vivo effects. To overcome the unfavorable pharmacokinetics and improve their effectiveness in prostate cancer, antibody-directed enzyme prodrug therapy (ADEPT) might offer a novel strategy to allow for restricted activation of ENL from circulating ENL-Gluc within the tumor environment...
January 23, 2017: AAPS PharmSciTech
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"